Core Viewpoint - Noble Mineral Exploration Inc. has successfully completed a non-brokered private placement, raising approximately $1.03 million to fund exploration activities in Ontario [2][5]. Private Placement - Noble raised gross proceeds of approximately $1,027,997.94 through the issuance of 17,133,299 flow-through common share units priced at $0.06 per unit [2]. - Each flow-through unit consists of one common share and one-half non-flow-through common share purchase warrant, with full warrants exercisable for two years at an exercise price of $0.10 per share [2]. - The company paid approximately $43,050 in cash commissions and issued 647,497 broker warrants, each exercisable for two years at an exercise price of $0.06 per share [3]. Regulatory Approvals - The private placement has received conditional approval from the TSX Venture Exchange and is subject to final approval [4]. Use of Proceeds - The proceeds from the private placement will be utilized for exploration expenditures on the company's properties located in Ontario [5]. Extension of Warrants - Noble has extended the term of 7,933,333 common share purchase warrants, which will now expire in November 2027 and December 2027 [6]. - Final approval for the extension of the warrants has been received from the Exchange [6]. Company Overview - Noble Mineral Exploration Inc. is a Canadian junior exploration company with holdings in various nickel and gold exploration properties [8]. - The company holds mineral and/or exploration rights in approximately 70,000 hectares in Northern Ontario and 24,000 hectares in Quebec [9]. - Notable projects include Project 81, which hosts drill-ready targets for gold, nickel-cobalt, and base metals [10].

Izotropic Announces Non-Brokered Private Placement & Extends WarrantsAugust 26, 2025 8:00 AM EDT | Source: Izotropic CorporationVancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 26, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announ ...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces that it has extended the expiry date of an aggregate of 4,752,969 outstanding warrants (the “2023 Warrants”). The 2023 Warrants were issued in connection with the clos ...